368 followers
RT @themsguide: @italoromeno @BacklundJames @PrincessMS23 @3_piets @rebekajah So far but not for MS. Yet. The relapsing MS trials in the…
RT @themsguide: @italoromeno @BacklundJames @PrincessMS23 @3_piets @rebekajah So far but not for MS. Yet. The relapsing MS trials in the…
@italoromeno @BacklundJames @PrincessMS23 @3_piets @rebekajah So far but not for MS. Yet. The relapsing MS trials in the tolebrutinib clinical trial program, GEMINI I and GEMINI II, are now fully enrolled. Regulatory timelines for this indication remain
#BTKinhibitors in the treatment of hematological malignancies and #inflammatorydiseases: mechanisms and clinical studies👇 https://t.co/CAwNd6Rph3 @SCUCN🇨🇳| #BCell https://t.co/Fsa9bbw0HA